KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested Capital

AbCellera Biologics (ABCL) Return on Invested Capital (2021 - 2023)

AbCellera Biologics' Return on Invested Capital history spans 3 years, with the latest figure at 0.16% for Q4 2023.

  • For the quarter ending Q4 2023, Return on Invested Capital fell 28.0% year-over-year to 0.16%, compared with a TTM value of 0.16% through Dec 2023, down 28.0%, and an annual FY2024 reading of 0.23%, down 6.0% over the prior year.
  • Return on Invested Capital for Q4 2023 was 0.16% at AbCellera Biologics, down from 0.14% in the prior quarter.
  • The five-year high for Return on Invested Capital was 0.19% in Q3 2022, with the low at 0.16% in Q4 2023.
  • Average Return on Invested Capital over 3 years is 0.03%, with a median of 0.11% recorded in 2022.
  • Year-over-year, Return on Invested Capital decreased -3bps in 2022 and then plummeted -32bps in 2023.
  • Tracing ABCL's Return on Invested Capital over 3 years: stood at 0.14% in 2021, then fell by -21bps to 0.11% in 2022, then plummeted by -246bps to 0.16% in 2023.
  • Per Business Quant, the three most recent readings for ABCL's Return on Invested Capital are 0.16% (Q4 2023), 0.14% (Q3 2023), and 0.1% (Q2 2023).